Series A Financing led by EcoR1 Capital, Jeito Capital and Syncona with continued support of strategic seed investors Vida Ventures, TPG and Two River Neogene’s proprietary technology platform ...

Partnership Combines Twist’s Leadership in DNA Synthesis and Synthetic Biology with Neogene’s Expertise in Personalized Engineered T Cell Therapies “Engineered T cell therapies have demonstrated ...

SANTA MONICA, Calif. & AMSTERDAM--(BUSINESS WIRE)--Neogene Therapeutics, Inc., a preclinical stage biotechnology company pioneering a new class of fully individualized T cell receptor (TCR) therapies ...

FILE PHOTO: A company logo is seen at the AstraZeneca site in Macclesfield (Reuters) -AstraZeneca will acquire biotechnology company Neogene Therapeutics for up to $320 million, the London-listed ...

As demand for 5G mobile phones increases, the vapor chamber (VC) is emerging to become a key component in 5G smartphone thermal management. Competition is keen among vapor chamber suppliers, and there ...

Nov 29 (Reuters) - AstraZeneca AZN.L said on Tuesday it would acquire Neogene Therapeutics, a developer of cell-based cancer treatments, for up to $320 million, as the London-listed drugmaker seeks to ...

AstraZeneca expanded its oncology portfolio Tuesday morning by announcing it reached an agreement to buy Neogene Therapeutics. The British pharma giant is purchasing the clinical-stage biotechnology ...

NeoGene Tech, a Guangzhou-based Taiwanese thermal management solution provider, has in Q3 2022 supported Xiaomi to successfully launch its flagship 5G smartphone, Xiaomi 12S Ultra, with excellent ...

LONDON – Neogene Therapeutics BV has raised $110 million in a series A round to advance development of a novel T-cell immunotherapy for treating solid tumors.

Raphaël Rousseau, M.D., Ph.D., is the latest biopharma vet to land at transatlantic biotech Neogene Therapeutics, where he joins a leadership bench of Kite and Bristol Myers Squibb veterans. Rousseau ...

Neogene aims to begin Phase I clinical studies in 2022. Neogene Therapeutics Inc. has raised $110 million in financing to advance the development of neo-antigen T cell therapies to treat various types ...

NEW YORK & AMSTERDAM--(BUSINESS WIRE)--Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, ...